Supplementary Figure 6 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404380

2023-01-01

Abstract:Pten null T-ALL blasts show lower levels of phospho-AKT in response to JQ1 in comparison to LICs.

What problem does this paper attempt to address?

Supplementary Figure 3 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404389

2023-01-01

Abstract:Cellular and biochemical effects of JQ1 in T-ALL.
Supplementary Figure 5 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404383

2023-01-01

Abstract:Primary human pediatric T-ALL samples show elevated levels of phospho-AKT.
Supplementary Figure 1 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404395.v1

2023-01-01

Abstract:Testing the efficacy of combination therapy using small molecules to reduce Pten null leukemia burden and LICs in vivo.
Supplementary Figure 4 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404386

2023-01-01

Abstract:Sensitivity of primary human pediatric T-ALL cells to rapamycin and JQ1 in vitro.
Supplementary Figure 7 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404377

2023-01-01

Abstract:DN thymocytes (DN3 and DN4) show highest levels of c-Myc in comparison to DP and SP populations.
Supplementary Figure 2 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404392

2023-01-01

Abstract:Cellular effects of rapamycin in T-ALL.
Data from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.c.6506591.v1

2023-01-01

Abstract:AbstractDisease relapse remains the major clinical challenge in treating T-cell acute lymphoblastic leukemia (T-ALL), particularly those with PTEN loss. We hypothesized that leukemia-initiating cells (LIC) are responsible for T-ALL development and treatment relapse. In this study, we used a genetically engineered mouse model of Pten−/− T-ALL with defined blast and LIC-enriched cell populations to demonstrate that LICs are responsible for therapeutic resistance. Unlike acute and chronic myelogenous leukemia, LICs in T-ALL were actively cycling, were distinct biologically, and responded differently to targeted therapies in comparison with their differentiated blast cell progeny. Notably, we found that T-ALL LICs could be eliminated by cotargeting the deregulated pathways driven by PI3K and Myc, which are altered commonly in human T-ALL and are associated with LIC formation. Our findings define critical events that may be targeted to eliminate LICs in T-ALL as a new strategy to treat the most aggressive relapsed forms of this disease. Cancer Res; 74(23); 7048–59. ©2014 AACR.
Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Table from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Suzanne Schubbert,Anjelica Cardenas,Harrison Chen,Consuelo Garcia,Wei Guo,James Bradner,Hong Wu

DOI: https://doi.org/10.1158/0008-5472.22404374

2023-01-01

Abstract:Supplementary Materials and Methods, Supplementary Figure Legends, and Characteristics of primary human pediatric T-ALL samples (Supplementary Table S1).
Ruxolitinib/nilotinib Cotreatment Inhibits Leukemia-Propagating Cells in Philadelphia Chromosome-Positive ALL.

Yuan Kong,Yi-Lin Wu,Yang Song,Min-Min Shi,Xie-Na Cao,Hong-Yan Zhao,Ya-Zhen Qin,Yue-Yun Lai,Hao Jiang,Qian Jiang,Xiao-Jun Huang

DOI: https://doi.org/10.1186/s12967-017-1286-5

IF: 8.44

2017-01-01

Journal of Translational Medicine

Abstract:BACKGROUND:As one of the major treatment obstacles in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), relapse of Ph+ALL may result from the persistence of leukemia-propagating cells (LPCs). Research using a xenograft mouse assay recently determined that LPCs were enriched in the CD34+CD38-CD58- fraction in human Ph+ALL. Additionally, a cohort study demonstrated that Ph+ALL patients with a LPCs phenotype at diagnosis exhibited a significantly higher cumulative incidence of relapse than those with the other cell phenotypes even with uniform front-line imatinib-based therapy pre- and post-allotransplant, thus highlighting the need for novel LPCs-based therapeutic strategies.METHODS:RNA sequencing (RNA-Seq) and real-time quantitative polymerase chain reaction (qRT-PCR) were performed to analyze the gene expression profiles of the sorted LPCs and other cell fractions from patients with de novo Ph+ALL. In order to assess the effects of the selective BCR-ABL and/or Janus kinase (JAK)2 inhibition therapy by the treatment with single agents or a combination of ruxolitinib and imatinib or nilotinib on Ph+ALL LPCs, drug-induced apoptosis of LPCs was investigated in vitro, as well as in vivo using sublethally irradiated and anti-CD122-conditioned NOD/SCID xenograft mouse assay. Moreover, western blot analyses were performed on the bone marrow cells harvested from the different groups of recipient mice.RESULTS:RNA-Seq and qRT-PCR demonstrated that JAK2 was more highly expressed in the sorted LPCs than in the other cell fractions in de novo Ph+ALL patients. Combination treatment with a selective JAK1/JAK2 inhibitor (ruxolitinib) and nilotinib more effectively eliminated LPCs than either therapy alone or both in vitro and in humanized Ph+ALL mice by reducing phospho-CrKL and phospho-JAK2 activities at the molecular level.CONCLUSIONS:In summary, this pre-clinical study provides a scientific rationale for simultaneously targeting BCR-ABL and JAK2 activities as a promising anti-LPCs therapeutic approach for patients with de novo Ph+ALL.
Supplemetal Data from Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Jin Zhang,Enshun Xu,Cong Ren,Hee Jung Yang,Yanhong Zhang,Wenqiang Sun,Xiangmudong Kong,Weici Zhang,Mingyi Chen,Eric Huang,Xinbin Chen

DOI: https://doi.org/10.1158/0008-5472.22417952

2023-01-01

Abstract:Supplemental Fig. S1 represents analysis of TLBL. Supplemental Fig. S2 contains representative images of H.E.-stained tumors. Supplemental Fig. S3 contains RT-PCR analysis of various genes (Tbet, NFAT1,NFAT2, IFNG, IL6) in thymus and TLBLs. Supplemental table S1-4 contains gender, survival, and tumor information of the mice.
Abstract B12: Co-inhibition of PI3K and Myc Pathways is Synthetic Lethal to PTEN Null T-ALL Leukemia-Initiating Cells

Suzanne Schubbert,Anjelica Cardenas,Christopher Wei,Lingda Ma,Consuelo Garcia,Wei Guo,Hong Wu

DOI: https://doi.org/10.1158/1535-7163.pms-b12

2013-01-01

Molecular Cancer Therapeutics

Abstract:Abstract T-cell acute lymphoblastic leukemia (T-ALL) is a common hematological malignancy associated with poor prognosis and significant risk of relapse. Loss of PTEN function due to mutations or deletions is common in primary T-ALL samples and is associated with resistance to therapeutic agents. We previously developed a VEC-Cre+;Ptenloxp/loxp (Pten null) T-ALL model to investigate the molecular and cellular mechanisms underlying T-ALL pathogenesis and resistance to therapy. Pten-null T-ALL develops after acquisition of a T cell receptor α/δ-c-myc translocation that causes c-Myc over-expression, and the leukemia-initiating cells, or leukemia stem cells (LSCs), are enriched in a c-kitmidCD3+ subpopulation. The goal of our current study is to develop improved therapeutic approaches to target LSCs and eliminate T-ALL. We hypothesize that small molecule inhibitors that target molecular lesions and pathways required for the development and survival of Pten null LSCs and T-ALL may be potent in eliminating LSCs and abolishing T-ALL. Rapamycin, an inhibitor of the PI3K downstream kinase mTOR, can suppress leukemia development in Pten null pre-leukemic mice, but is insufficient to eliminate LSCs and T-ALL. Therefore, we are investigating the therapeutic utility of combinational therapies that co-target multiple deregulated pathways that are critical for LSC formation and T-ALL survival. We found that combination treatment of Pten null T-ALL mice with rapamycin and VX-680, an Aurora kinase inhibitor shown to have synthetic lethality with Myc over-expression, causes robust elimination of leukemia blasts and significantly diminishes the LSC population. Functional studies for leukemia-initiating-cell activity using transplantation of treated bone marrow into NOD-SCID-IL2rγ-/-(NSG) recipients showed that dual treatment reduced leukemia-initiating-cell activity in bone marrow by at least 100-fold in comparison to single agent alone. Importantly, a large portion of Pten null T-ALL LSCs are actively cycling (~50% in S-phase), which may contribute to the mechanism underlying the efficacy of VX-680. We have developed a T-ALL in vitro culture system derived from primary Pten null T-ALL mice to conduct more detailed evaluation of the cellular and biochemical effects of rapamycin and VX-680, perform mechanistic analysis, and screen additional cell cycle-directed and Myc-targeted agents. We found that Pten null T-ALL is highly sensitive to killing by the CDK1 inhibitor purvalanol and JQ1, a bromodomain inhibitor reported to down-regulate c-myc expression that is suitable for use in vivo. Rapamycin and JQ1 combination treatment of Pten null T-ALL mice causes a significant reduction in both the leukemia blast and LSC populations, similar to the effects of rapamycin and VX-680 combination therapy. Our results highlight the importance of understanding the mechanisms underlying T-ALL development and survival and show potent synthetic lethality of PI3K and Myc pathway co-inhibition in PTEN null T-ALL LSCs. Importantly, such targeted combination therapy may offer an improved therapeutic approach to treat human T-ALL. Citation Format: Suzanne Schubbert, Anjelica Cardenas, Christopher Wei, Lingda Ma, Consuelo Garcia, Wei Guo, Hong Wu. Co-inhibition of PI3K and Myc pathways is synthetic lethal to PTEN null T-ALL leukemia-initiating cells. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Synthetic Lethal Approaches to Cancer Vulnerabilities; May 17-20, 2013; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(5 Suppl):Abstract nr B12.
Suppression of Leukemia Development Caused by Pten Loss

Wei Guo,Suzanne Schubbert,James Y. Chen,Bahram Valamehr,Sherly Mosessian,Hubing Shi,Nhi H. Dang,Consuelo Garcia,Mariana F. Theodoro,Marileila Varella-Garcia,Hong Wu

DOI: https://doi.org/10.1073/pnas.1006937108

2011-01-01

Abstract:Multiple genetic or molecular alterations are known to be associated with cancer stem cell formation and cancer development. Targeting such alterations, therefore, may lead to cancer prevention. By crossing our previously established phosphatase and tensin homolog (Pten) - null acute T-lymphoblastic leukemia (T-ALL) model onto the recombination-activating gene 1 −/− background, we show that the lack of variable, diversity and joining [V(D)J] recombination completely abolishes the Tcrα/δ-c-myc translocation and T-ALL development, regardless of β-catenin activation. We identify mammalian target of rapamycin (mTOR) as a regulator of β-selection. Rapamycin, an mTOR-specific inhibitor, alters nutrient sensing and blocks T-cell differentiation from CD4 − CD8 − to CD4 + CD8 + , the stage where the Tcrα/δ-c-myc translocation occurs. Long-term rapamycin treatment of preleukemic Pten -null mice prevents Tcrα/δ-c-myc translocation and leukemia stem cell (LSC) formation, and it halts T-ALL development. However, rapamycin alone fails to inhibit mTOR signaling in the c-Kit mid CD3 + Lin − population enriched for LSCs and eliminate these cells. Our results support the idea that preventing LSC formation and selectively targeting LSCs are promising approaches for antileukemia therapies.
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

Christian Hurtz,Katerina Hatzi,Leandro Cerchietti,Melanie Braig,Eugene Park,Yong-mi Kim,Sebastian Herzog,Parham Ramezani-Rad,Hassan Jumaa,Martin C Müller,Wolf-Karsten Hofmann,Andreas Hochhaus,B Hilda Ye,Anupriya Agarwal,Brian J Druker,Neil P Shah,Ari M Melnick,Markus Müschen

DOI: https://doi.org/10.1084/jem.20110304

2011-10-24

Abstract:Chronic myeloid leukemia (CML) is induced by the oncogenic BCR-ABL1 tyrosine kinase and can be effectively treated for many years with tyrosine kinase inhibitors (TKIs). However, unless CML patients receive life-long TKI treatment, leukemia will eventually recur; this is attributed to the failure of TKI treatment to eradicate leukemia-initiating cells (LICs). Recent work demonstrated that FoxO factors are critical for maintenance of CML-initiating cells; however, the mechanism of FoxO-dependent leukemia initiation remained elusive. Here, we identified the BCL6 protooncogene as a critical effector downstream of FoxO in self-renewal signaling of CML-initiating cells. BCL6 represses Arf and p53 in CML cells and is required for colony formation and initiation of leukemia. Importantly, peptide inhibition of BCL6 in human CML cells compromises colony formation and leukemia initiation in transplant recipients and selectively eradicates CD34(+) CD38(-) LICs in patient-derived CML samples. These findings suggest that pharmacological inhibition of BCL6 may represent a novel strategy to eradicate LICs in CML. Clinical validation of this concept could limit the duration of TKI treatment in CML patients, which is currently life-long, and substantially decrease the risk of blast crisis transformation.
Targeting the PIM Protein Kinases for the Treatment of a T-cell Acute Lymphoblastic Leukemia Subset

Sathish Kumar Reddy Padi,Libia A. Luevano,Ningfei An,Ritu Pandey,Neha Singh,Jin H. Song,Jon C. Aster,Xue-Zhong Yu,Shikhar Mehrotra,Andrew S. Kraft

DOI: https://doi.org/10.18632/oncotarget.16320

2017-01-01

Oncotarget

Abstract:New approaches are needed for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) who fail to achieve remission with chemotherapy. Analysis of the effects of pan-PIM protein kinase inhibitors on human T-ALL cell lines demonstrated that the sensitive cell lines expressed higher PIM1 protein kinase levels, whereas T-ALL cell lines with NOTCH mutations tended to have lower levels of PIM1 kinase and were insensitive to these inhibitors. NOTCH-mutant cells selected for resistance to gamma secretase inhibitors developed elevated PIM1 kinase levels and increased sensitivity to PIM inhibitors. Gene profiling using a publically available T-ALL dataset demonstrated overexpression of PIM1 in the majority of early T-cell precursor (ETP)-ALLs and a small subset of non-ETP ALL. While the PIM inhibitors blocked growth, they also stimulated ERK and STAT5 phosphorylation, demonstrating that activation of additional signaling pathways occurs with PIM inhibitor treatment. To block these pathways, Ponatinib, a broadly active tyrosine kinase inhibitor (TKI) used to treat chronic myelogenous leukemia, was added to this PIM-inhibitor regimen. The combination of Ponatinib with a PIM inhibitor resulted in synergistic T-ALL growth inhibition and marked apoptotic cell death. Treatment of mice engrafted with human T-ALL with these two agents significantly decreased the tumor burden and improved the survival of treated mice. This dual therapy has the potential to be developed as a novel approach to treat T-ALL with high PIM expression.
Additional File 1 of Super-enhancer Profiling Identifies Novel Critical and Targetable Cancer Survival Gene LYL1 in Pediatric Acute Myeloid Leukemia

Fang,Jun Lü,Zi-Mu Zhang,Xiaolu Li,Yi Xie,Shuiyan Wu,Xinran Chu,Gen Li,Di Wu,Yanling Chen,Juanjuan Yu,Si-qi Jia,Chenxi Feng,Yuanyuan Tian,Li,Jing Ling,Shaoyan Hu,Jian Pan

DOI: https://doi.org/10.6084/m9.figshare.20329680

2022-01-01

Abstract:Additional file 1: Supplementary Table 1. Treatment and outcome of 11 pediatric AML patients included in ChIP-seq analysis.
PI3Kγ maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway

Hao Gu,Chiqi Chen,Zhi-Shuai Hou,Xia-Di He,Shaozhen Xie,Jing Ni,Changli Qian,Xin Cheng,Tao Jiang,Ce Yang,Thomas M. Roberts,Junke Zheng,Judith A. Varner,Scott A. Armstrong,Jean J. Zhao

DOI: https://doi.org/10.1182/blood.2023022202

IF: 20.3

2024-01-27

Blood

Abstract:PI3Kγ functions as a critical enzyme in acute myeloid leukemia development but not in normal hematopoiesis. Targeting PI3Kγ represents a promising therapy that could improve outcomes and reduce toxicity compared to the current standard of care. Acute myeloid leukemia (AML) is an aggressive hematological malignancy originating from transformed hematopoietic stem/progenitor cells. AML prognosis remains poor, due to resistance and relapse driven by leukemia stem cells (LSCs). Targeting molecules essential for LSC function is a promising therapeutic approach. The PI3K/AKT pathway is often dysregulated in AML. We found while that PI3Kγ is highly enriched in LSCs and critical for self-renewal, it was dispensable for normal hematopoietic stem cells. Mechanistically, PI3Kγ-AKT signaling promotes NRF2 nuclear accumulation, which induces PGD and the pentose phosphate pathway, thereby maintaining LSC stemness. Importantly, genetic or pharmacological inhibition of PI3Kγ impaired expansion and stemness of murine and human AML cells in vitro and in vivo. Together, our findings reveal a key role for PI3Kγ in selectively maintaining LSC function by regulating AKT-NRF2-PGD metabolic pathway. Targeting the PI3Kγ pathway may therefore eliminate LSCs without damaging normal hematopoiesis, providing a promising therapeutic strategy for AML.

hematology
Abstract 5820: Targeting the PIM Protein Kinases for the Treatment of a T-cell Acute Lymphoblastic Leukemia Subset

Sathish Kumar Reddy Padi,Libia Luevano,Neha Singh,Jiin Song,Ritu Pandey,Jon C. Aster,Xue-Zhong Yu,Shikhar Mehrotra,Andrew Kraft

DOI: https://doi.org/10.1158/1538-7445.am2017-5820

IF: 11.2

2017-01-01

Cancer Research

Abstract:Abstract While intensive chemotherapy regimens result in remission in approximately 80% of pediatric and 45% of adult ALL patients, new approaches are needed for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) who fail to achieve remission with chemotherapy. Early T-cell precursor (ETP) ALL, a subset of T-ALL associated with a higher rate of relapse and induction failure, with a 10-year overall survival of 19% as compared with 84% for all other T-ALLs. PIM protein kinases are overexpressed in a number of hematopoietic malignancies, including ALL, with its overexpression being associated with poor prognosis. Pan-PIM inhibitors (PIMi) are being tested in clinical trials in patients with relapsed/refractory multiple myeloma and acute myeloid leukemia. Analysis of the effects of PIMi (AZD1208/LGB321) on human T-ALL cell lines demonstrated that the sensitive cell lines expressed higher PIM1 levels, whereas T-ALL cell lines with NOTCH mutations tended to have lower levels of PIM1 kinase and were insensitive to these inhibitors. NOTCH-mutant cells selected for resistance to gamma secretase inhibitors developed elevated PIM1 kinase levels and increased sensitivity to PIM inhibitors. Immunophenotype of all the PIMi insensitive cells lines was consistent with a more mature T-ALL phenotype. In contrast, sensitive cells, had an immature or ETP-ALL phenotype. Bioinformatics analysis of three independent T-ALL patient datasets (GSE28703, E-MEXP-313, and GSE62156) demonstrated overexpression of PIM1 in the majority of ETP-ALLs and in a small subset of non-ETP-ALL. We also identified 58 genes changing significantly between PIMi sensitive versus insensitive cell lines that were common to the differential genes between ETP versus non-ETP ALL cases from GSE28703, suggesting that high PIM1 expression along with 58 gene signature could be a driver of the ETP phenotype. Importantly, we have made the novel observation that, combination of Ponatinib, a tyrosine kinase inhibitor (TKI) with the PIMi is synergistically lethal to T-ALL cells with ETP phenotype. These agents appear to work together by inducing PARP and Caspase cleavage, sufficient to drive apoptosis. Following engraftment of NSG mice with H-SB2-Luc cells, three weeks of dual therapy with AZD1208 (30mg/kg/day) and Ponatinib (3mg/kg/day) significantly abrogated leukemia as evidenced by optical scanning for luciferase cells, and reduced number of hCD45+ leukemic cells in the peripheral blood and bone marrow. Also, the dual therapy significantly prolonged the survival of the treated mice. In summary, our work demonstrates a strong preclinical rationale for a novel treatment strategy of combining PIMi and TKI to treat T-ALL patients with high PIM expression. Citation Format: Sathish Kumar Reddy Padi, Libia Luevano, Neha Singh, Jiin Song, Ritu Pandey, Jon C. Aster, Xue-Zhong Yu, Shikhar Mehrotra, Andrew Kraft. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5820. doi:10.1158/1538-7445.AM2017-5820
Single Cell RNA-Seq Reveals Deranged Developmental Hierarchy with Coexisting Oncogenic States and Immune Evasion Programs in ETP T-ALL

Amy Guillaumet-Adkins,Praveen Anand,Huiyoung Yun,Yotam Drier,Anna Rogers,Madhu M. Ouseph,Monica S. Nair,Sayalee Potdar,Randi Isenhart,Jake A. Kloeber,Tushara Vijaykumar,Guangwu Guo,Julia Frede,Marian H. Harris,Lewis B. Silverman,Andrew A. Lane,Daniel J. DeAngelo,Jon C. Aster,Bradley E. Bernstein,Jens G. Lohr,Birgit Knoechel

DOI: https://doi.org/10.1182/blood-2019-130482

IF: 20.3

2019-11-13

Blood

Abstract:Introduction: Early T-cell precursor acute lymphoblastic leukemia (ETP T-ALL) is a distinct subtype of T-ALL characterized by higher rates of relapse and induction failure. Large-scale genetic sequencing studies have identified frequently mutated oncogenes and gene fusions in ETP T-ALL, while bulk transcriptome analyses have revealed expression features resembling myeloid precursors and myeloid malignancies. However, the contributions of intra-tumoral functional heterogeneity and microenvironment to tumor biology and treatment failure remain unknown. Methods: We performed full-length single-cell RNA-sequencing of 5,077 malignant and normal immune cells from bone marrow or blood from five patients with relapsed/refractory ETP T-ALL (based on immunophenotyping, all with NOTCH1 mutations), before and after targeted therapy against NOTCH1. These patients were enrolled on a phase I trial with the γ-secretase inhibitor (GSI) BMS-906024 (NCT01363817). Expression of selected genes was validated by RT-PCR, flow cytometry and immunohistochemistry. Results: Single cell transcriptome analyses revealed a deranged developmental hierarchy characterized by co-expression of stemness programs in multiple malignant cells implying ineffectual commitment to either lymphoid or myeloid lineage. Most ETP T-ALL cells co-expressed HSC (hematopoietic stem cell), CMP (common myeloid progenitor) and CLP (common lymphoid progenitor) signatures simultaneously (Pearson correlation: CLP-CMP: R= 0.41, p < 2.2e-16; HSC-CLP: R= 0.53; p < 2.2e-16; HSC-CMP: R = 0.39, p <2.2e-16). Only a fraction of cells (less than 15%) demonstrated mutually exclusive CLP or HSC signatures. In contrast, CLP, CMP and HSC signatures were not co-expressed and always negatively correlated in normal bone marrow cells (CLP-CMP: R= -0.11, p < 2.2e-16; HSC-CLP: R= -0.38; p < 2.2e-16; HSC-CMP: R = -0.67, p <2.2e-16). Direct targeting of NOTCH1 as the driving oncogene has shown disappointing results in the clinical setting due to the rapid development of resistance. PI3K activation has been shown as a genetic mechanism of Notch resistance, however it is unclear if transcriptional rewiring can give rise to PI3K dependent cells after Notch inhibition. To address this question, we predicted the activity of signaling pathways in single cells after Notch inhibitor treatment using PROGENy. Most single cells demonstrated loss of Notch signaling. PI3K signaling activity was the most anti-correlated signaling pathway to Notch signaling (Pearson correlation: R= -0.51, p < 2.2e-16). Of note, this population preexisted at a frequency of ~30% in the untreated population, coexisting with cells with high Notch activation. Analysis of the immune microenvironment revealed an oligoclonal T-cell population in ETP T-ALL compared to normal donor T-cells. CD8+ T-cells from ETP patients expressed markers of T-cell exhaustion (PDCD1, TIGIT, LAG3, HAVCR2). Analyses of expression levels of the respective ligands on leukemic blasts and the predicted interaction with their receptors on endogenous CD8+ T-cells demonstrated the highest interaction score between HAVCR2 and its ligand LGALS9. LGALS9 was universally expressed in all leukemic cells, which was confirmed by flow cytometry staining in leukemic blasts and IHC staining in bone marrow of 8 patients with ETP T-ALL and 7 patients with T-ALL. T-ALL supernatant increased expression levels of the exhaustion markers HAVCR2,TIGIT and decreased effector marker GZMB in polyclonal activated normal donor CD8+ T-cells (RT-PCR). This effect was abrogated by neutralizing LGALS9 and could be rescued with recombinant LGALS9. Conclusion: We identified deranged developmental hierarchy characterized by co-expression of stemness programs in multiple malignant cell states and ineffectual commitment to either lymphoid or myeloid lineage in ETP T-ALL. Leukemic blasts demonstrate preexisting heterogeneity of diverse oncogenic states as evidenced by opposing PI3K and Notch activity, suggesting possible novel combination therapies. Notch inhibition abolishes the Notch high state without effecting the PI3K active state. Finally, we demonstrate a possible role for HAVCR2-LGALS9 interactions in causing CD8+ T-cell dysfunction in ETP T-ALL patients, which may provide a novel therapeutic strategy in this disease. Disclosures Silverman: Takeda: Consultancy; Servier: Consultancy, Research Funding. Lane:AbbVie: Research Funding; Stemline Therapeutics: Research Funding; N-of-One: Consultancy. DeAngelo:Glycomimetics: Research Funding; Amgen, Autolus, Celgene, Forty-seven, Incyte, Jazzs, Pfizer, Shire, Takeda: Consultancy; Blueprint: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Abbvie: Research Funding. Lohr:Celgene: Research Funding; T2 Biosystems: Honoraria.

hematology

Supplementary Figure 6 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Figure 3 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Figure 5 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Figure 1 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Figure 4 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Figure 7 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Figure 2 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Data from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Table from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Ruxolitinib/nilotinib Cotreatment Inhibits Leukemia-Propagating Cells in Philadelphia Chromosome-Positive ALL.

Supplemetal Data from Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Abstract B12: Co-inhibition of PI3K and Myc Pathways is Synthetic Lethal to PTEN Null T-ALL Leukemia-Initiating Cells

Suppression of Leukemia Development Caused by Pten Loss

BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

Targeting the PIM Protein Kinases for the Treatment of a T-cell Acute Lymphoblastic Leukemia Subset

Additional File 1 of Super-enhancer Profiling Identifies Novel Critical and Targetable Cancer Survival Gene LYL1 in Pediatric Acute Myeloid Leukemia

PI3Kγ maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway

Abstract 5820: Targeting the PIM Protein Kinases for the Treatment of a T-cell Acute Lymphoblastic Leukemia Subset

Single Cell RNA-Seq Reveals Deranged Developmental Hierarchy with Coexisting Oncogenic States and Immune Evasion Programs in ETP T-ALL